Comparative Pharmacology
Head-to-head clinical analysis: CYCLOGYL versus ISOPTO ATROPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOGYL versus ISOPTO ATROPINE.
CYCLOGYL vs ISOPTO ATROPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blocks muscarinic acetylcholine receptors (M1-M5), inhibiting parasympathetic nerve impulses that cause constriction of the ciliary muscle and sphincter muscle of the iris, resulting in cycloplegia (ciliary muscle paralysis) and mydriasis (pupil dilation).
Antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, resulting in mydriasis and cycloplegia.
1-2 drops of 0.5% or 1% solution in conjunctival sac, may repeat in 5-10 minutes if needed, up to every 4-6 hours.
1 to 2 drops of 1% solution in the affected eye(s) up to four times daily for cycloplegic refraction; for uveitis, 1 to 2 drops up to three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5 to 0.75 hours in adults; in children, it may be slightly shorter. Clinical context: short half-life allows repeated administration for mydriasis and cycloplegia.
2.5-3.0 hours (terminal elimination half-life in adults); may be prolonged in elderly and children due to reduced metabolic clearance
Renal excretion of unchanged drug accounts for less than 5% of elimination; the majority is metabolized in the liver and excreted in urine as metabolites. Biliary/fecal excretion is minimal (<2%).
Renal (70% as unchanged drug and metabolites within 24 hours); fecal (30%)
Category C
Category C
Ophthalmic Anticholinergic
Ophthalmic Anticholinergic